This trial is evaluating whether Telatinib will improve 1 primary outcome and 4 secondary outcomes in patients with Carcinoma, Hepatocellular. Measurement will happen over the course of from the start of treatment until 30 days following the end of treatment or until initiation of a new anticancer therapy (whichever occurs first), approximately 13 months.
This trial requires 45 total participants across 2 different treatment groups
This trial involves 2 different treatments. Telatinib is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
There is no experimental evidence to support the belief that hepatocellular carcinoma can be cured. When cured, the patient has an increased risk of developing liver cancer. Because the risk is more pronounced in younger patients with cirrhosis or HBV-infection, this disease should be carefully evaluated and treated to reduce the risk of developing liver cancer after cure.
The most common form of [liver cancer](https://www.withpower.com/clinical-trials/liver-cancer) – hepatocellular carcinoma (HCC) – is one of the leading causes of cancer-related deaths in China. The 5-year survival rate is 38% in China. The major risk factors for HCC in China include cirrhosis, hepatitis B infection, aflatoxin B1 contamination and alcohol consumption. Treatment of HCC largely depends on the stage of the disease. Surgery alone is generally recommended in patients at early stages and those in good condition; radiotherapy or chemotherapy is normally recommended for patients with advanced HCC, those at the late stages, or those who have recently undergone surgery and are unwell. Prognosis depends on the stage of HCC.
The most common site of hepatocarcinoma is the cirrhotic liver. More than 90% of HCCs are metastasized when they are discovered, and about 50% of the patients present with liver cirrhosis. Cirrhosis, hepatitis B and a long delay from HBV infection determine the development of HCC. Atypical morphology, hepatitis B surface antigen negativity. and hepatitis C virus infection increase the risk of HCC.
There is the potential to prevent ∼300,000 new cases of carcinoma, hepatocellular in women and men annually in the US. However, there remains no clear evidence that any current screening strategy is effective except for an annual pap smear for women and men over age 70 years.
A combination of chemotherapy regimen for the treatment of HCC is a good option. The treatment of HCC does not include curative treatments; however, it can improve the quality of life and the patients' physical condition.
The signs in liver function are similar both for HCC and for HCV. Hepatocellular carcinoma should be suspected in the presence of the following (in order of importance): alpha-fetoprotein >100 ng/ml or AFP/Albumin >50% ratio, tumor size >5 cm or BCL10 expression, hepatic venous outflow obstruction, and in patients with low BMI and cirrhosis, unexplained weight loss and anemia. HCC should be suspected by the presence of nodular lesions or masses.
There may be additional benefit to the use of telatinib for patients with progressive advanced HCCs due to the potential for significant reduction in disease progression-related deaths.
Telatinib may delay hepatocellular carcinoma progression after hepatic resection. Because of the slow absorption rate, it was more cost-effective to use telatinib for a longer period after surgery than to take the drug more frequently. Future studies are still necessary to determine the optimal dosing and duration of therapy.
Telatinib is a small molecule kinase inhibitor and Bcr-a-kit tyrosine kinase inhibitor (ATKI) which has been developed to treat acute myelogenous leukaemias (AML)-related disease such as blast crisis, and chronic myelogenous leukaemia. Currently, there are numerous clinical trials (Phase II and IIIa) to examine the efficacy, safety and tolerability of telatinib in adult patients with AML. Some patients may show resistance to current treatments from the use or misuse of drugs.
We found no evidence that patients with carcinoma, hepatocellular, should be considered for clinical trials, as current therapeutic strategies are insufficient to prevent progression of the disease, although we observed a statistically significant probability of disease control. A prospective controlled trial to verify our findings is warranted.
Hepatocellular carcinoma is not a heritable disease. A family history of HCC is significantly linked to male sex, older age and hepatitis B virus infection, which are all risk factors of HCC. Data from a recent study suggest HCC is not a heritable disease.
The most effective anti-carcinogenic therapy was found to be a combination of p53 monoclonal antibody, bacillus Calmette-Guérin, and alkylating agents. The efficacy of these therapies in the treatment of HCC remains to be determined.